Celcuity Inc.

Listed Company

CELCCIK 0001603454NasdaqNon-AcceleratedSmaller ReportingServices-Medical LaboratoriesDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-177.04M

Total Assets

$466.56M

Equity

$100.56M

Shares Out

48.34M

Op. Cash Flow

$-153.28M

Business

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumors. Its principal product candidate is gedatolisib, an intravenously administered small molecule that inhibits all Class I PI3K isoforms and both mTORC1 and mTORC2 complexes. Key business programs include clinical development activities in HR+/HER2- advanced or metastatic breast cancer and metastatic castration-resistant prostate cancer, plus the CELsignia diagnostic platform (reduced activity). Clinical development and potential commercialization activities span North America, Europe, Latin America and Asia‑Pacific through multicenter trial sites and potential commercial partnerships or a targeted sales force.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	145	104	61	35	26
General and administrative	27	9	6	4	3
Total operating expenses	172	113	66	39	28
Loss from operations	−172	−113	−66	−39	−28
Interest expense	−17	−10	−5	—	—
Interest income	12	12	8	1	13,262
Other (expense) income, net	−5	1	2	—	—
Net loss before income taxes	−177	−112	−64	−40	−30
Income taxes	—	—	—	—	—
Net loss	−177	−112	−64	−40	−30
Net loss per share, basic	−3.79	−2.83	−2.69	−2.64	−2.21
Net loss per share, diluted	−3.79	−2.83	−2.69	−2.64	—
Weighted average common shares outstanding, basic	47	39	24	15	13
Weighted average common shares outstanding, diluted	47	39	24	15	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	166	23	31	25	84
Investments	276	213	150	144	—
Prepaid clinical trial costs	19	7	—	—	—
Other current assets	5	3	10	7	—
Total current assets	466	245	191	175	85
Property and equipment, net	499,000	336,000	228,782	260,294	312,444
Operating lease right-of-use assets	51,000	216,000	400,019	246,266	241,901
Other non-current assets	349,000	—	—	—	—
Total assets	467	245	191	176	86
Accounts payable	6	9	5	3	2
Accrued clinical trial costs	17	17	—	—	—
Other accrued expenses	21	5	—	—	—
Operating lease liabilities, current	54,000	172,000	184,950	191,749	189,858
Total current liabilities	44	32	14	7	3
Operating lease liabilities, non-current	—	54,000	225,922	61,002	61,771
Convertible debt	195	—	—	—	—
Note payable, non-current	127	98	37	35	15
Total liabilities	366	130	51	42	17
Commitments and contingencies (Note 7)	—	—	—	—	—
Preferred stock, $0.001 par value: 2,500,000 shares authorized as of December 31, 2025 and 2024; 0 and 317,577 shares issued and outstanding as of December 31, 2025 and 2024, respectively	—	—	854	1,121	—
Common stock, $0.001 par value: 95,000,000 shares authorized as of December 31, 2025 and 2024; 48,244,960 and 37,143,242 shares issued and outstanding as of December 31, 2025 and 2024, respectively	48,000	37,000	25,506	21,667	14,919
Additional paid-in capital	549	387	300	230	125
Accumulated deficit	−449	−272	−160	−96	−56
Total stockholders equity	101	116	140	134	69
Total liabilities and stockholders equity	467	245	191	176	86

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	200,000	100,000	142,772	210,918	303,235
Stock-based compensation	21	7	5	5	3
Amortization of debt issuance costs and discount	3	1	241,752	395,757	267,821
Payment-in-kind interest	1	1	2	455,074	300,001
Non-cash operating lease expense	−7,000	—	4,368	—	—
Change in accrued interest income	630,000	150,000	−993,457	—	—
Prepaid clinical trial costs	−12	−2	—	—	—
Other current and non-current assets	−3	3	−3	−6	—
Accounts payable	−3	4	2	1	1
Accrued clinical trial costs	118,000	10	—	—	—
Other accrued expenses	15	3	—	—	—
Net cash used in operating activities	−153	−83	−54	−36	−20
Proceeds from maturities of investments	333	642	310	—	—
Purchases of investments	−396	−705	−315	−144	—
Purchases of property and equipment	−249,000	−250,000	−97,644	−158,768	−81,898
Net cash used in investing activities	−64	−63	−5	−144	−81,398
Proceeds from employee stock purchases	711,000	276,000	202,845	171,710	—
Proceeds from exercise of common stock options	3	770,000	388,522	152,412	63,420
Proceeds from exercise of common stock warrants	42	15	22,505	—	18,762
Proceeds from convertible debt, net of debt issuance costs of $6,246 and $0 during the years ended December 31, 2025 and 2024, respectively	195	—	—	—	—
Proceeds from note payable, net of debt issuance costs of $2,255 and $2,438 during the years ended December 31, 2025 and 2024, respectively	28	59	—	20	14
Proceeds from equity offering, net of underwriting discounts and offering costs	92	56	—	—	—
Proceeds from an ATM offering, net of issuance costs	—	7	14	—	—
Payments for secondary registration statement costs	−46,000	−228,000	−45,805	—	—
Net cash provided by financing activities	361	138	65	120	93
Net change in cash and cash equivalents	143	−8	6	−60	73
Cash paid for interest	10	8	3	1	694,528
Cash paid for operating leases	220,000	325,000	—	—	—
Common stock warrants issued with the note payable transaction	3	1	—	—	—
Property and equipment included in accounts payable	82,000	1,000	13,615	—	—
Deferred financing, offering and registration statement costs included in accounts payable	—	42,000	56,414	51,020	8,123

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro